期刊文献+

Recent research and progress of biodegradable zinc alloys and composites for biomedical applications: Biomechanical and biocorrosion perspectives 被引量:18

原文传递
导出
摘要 Biodegradable metals(BMs)gradually degrade in vivo by releasing corrosion products once exposed to the physiological environment in the body.Complete dissolution of biodegradable implants assists tissue healing,with no implant residues in the surrounding tissues.In recent years,three classes of BMs have been extensively investigated,including magnesium(Mg)-based,iron(Fe)-based,and zinc(Zn)-based BMs.Among these three BMs,Mg-based materials have undergone the most clinical trials.However,Mg-based BMs generally exhibit faster degradation rates,which may not match the healing periods for bone tissue,whereas Fe-based BMs exhibit slower and less complete in vivo degradation.Zn-based BMs are now considered a new class of BMs due to their intermediate degradation rates,which fall between those of Mg-based BMs and Fe-based BMs,thus requiring extensive research to validate their suitability for biomedical applications.In the present study,recent research and development on Zn-based BMs are reviewed in conjunction with discussion of their advantages and limitations in relation to existing BMs.The underlying roles of alloy composition,microstructure,and processing technique on the mechanical and corrosion properties of Zn-based BMs are also discussed.
机构地区 School of Engineering
出处 《Bioactive Materials》 SCIE 2021年第3期836-879,共44页 生物活性材料(英文)
基金 support for this research by the Australian Research Council(ARC)through the discovery grant DP170102557 and ARC Future Fellowship(FT160100252) YL is also supported through an ARC Future Fellowship(FT160100252).
  • 相关文献

参考文献29

二级参考文献307

  • 1G.L. Song, S.Z. Song, Adv. Eng. Mater. 9 (2007) 298-302.
  • 2F. Witte, V. Kaese, H. Haferkamp, E. Switzer, A. Meyer-Lindenberg, C.J. Wirth, H. Windhagen, Biomaterials 26 (2005) 3.
  • 3J.C. Gao, S. Wu, L.Y. Qiao, Y. Wang, Trans. Nonferrous Met. Soc. China 18 (2008) 588-592.
  • 4B. Heublein, R. Rohde, V. Kaese, M. Niemeyer, W. Hartung, A. Haverich, Heart 89 (2003) 651-656.
  • 5C.D. Mario, H. Griffiths, O. Goktekin, J. Interv. Cardiol. 17 (2004) 391-395.
  • 6P. Peeters, M. Bosiers, J. Verbist, K. Deloose, B. Heublein, J. Endovascular Ther. 12 (2005) 1-5.
  • 7R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F.R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horriga.
  • 8R. Waksman, EuroIntervention 5 (2009) FI03-FI08.
  • 9S.S.A. El-Rahman, Pharmacol. Res. 47 (2003) 189-194.
  • 10Y Nakamura, Y Tsumura, Y. Tonogai, T. Shibata, Y Ito, Toxicol. Sci. 37 (1997) 106-116.

共引文献284

同被引文献167

引证文献18

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部